8-K: Invivyd Reports $11.3 Million in Q1 2025 PEMGARDA Revenue, Targets Near-Term Profitability

Invivyd announces Q1 2025 financial results, highlighting $11.3 million in PEMGARDA net product revenue and a strategic focus on achieving profitability in the first half of 2025.

Summary

• Invivyd reported $11.3 million in PEMGARDA net product revenue for Q1 2025.
• This revenue was influenced by a planned transition from a contracted to an internalized sales force in January/February 2025.
• The company observed a re-acceleration of PEMGARDA revenue in Q2 2025 to date.
• Invivyd is targeting near-term profitability (1H 2025) with existing cash and cash equivalents, anticipated growth of net product revenue, and continued reduction of operating expenses.
• As of March 31, 2025, Invivyd had $48.1 million in cash and cash equivalents.
• R&D expenses for Q1 2025 were $10.6 million, compared to $31.2 million for the same period in 2024.
• SG&A expenses for Q1 2025 were $16.8 million, compared to $14.9 million for the same period in 2024.
• Net loss for Q1 2025 was $16.3 million, compared to $43.5 million for the same period in 2024.
• Basic and diluted net loss per share was $0.14 for Q1 2025, compared to $0.38 for the same period in 2024.
• In April 2025, Invivyd secured a $30 million non-dilutive term loan facility with Silicon Valley Bank.

Sentiment

Score: 6

Explanation: The sentiment is cautiously optimistic. While Q1 revenue was down, the company is projecting profitability in the near term and has secured additional funding. The pipeline expansion and focus on a conserved epitope are also positive signs, but the FDA declination and competitive landscape present challenges.

Positives

• PEMGARDA uptake continues to grow among healthcare providers.
• PEMGARDA shows sustained neutralizing activity against dominant SARS-CoV-2 variants.
• PEMGARDA safety profile remains consistent with the Fact Sheet for Healthcare Providers.
• Invivyd secured a $30 million non-dilutive term loan facility.
• R&D expenses have decreased significantly year-over-year.
• Net loss has decreased significantly year-over-year.
• Invivyd is targeting near-term profitability (1H 2025).
• Invivyd is launching an educational COVID-19 campaign highlighting the continued morbidity and mortality year-round threat of COVID-19.
• PEMGARDA is priced for value for patients below nearly all FDA-approved monoclonal antibodies launched in the past 5 years.

Negatives

• PEMGARDA revenue was influenced by a planned transition from a contracted to an internalized sales force in January/February 2025.
• The FDA declined Invivyd's request to expand the existing EUA of PEMGARDA to include treatment of mild-to-moderate COVID-19 for certain immunocompromised patients.
• Cash and cash equivalents decreased from $69.3 million at the end of 2024 to $48.1 million as of March 31, 2025.

Risks

• The company's ability to achieve and sustain profitability is subject to various factors, including market acceptance of PEMGARDA and continued reduction of operating expenses.
• The EUA for PEMGARDA could be revised or revoked by the FDA.
• The company faces competition from other pharmaceutical companies in the development and commercialization of COVID-19 treatments.
• Unexpected safety or efficacy data observed during preclinical studies or clinical trials could impact the development of product candidates.
• The company's reliance on third parties for manufacturing and other services poses a risk to its operations.
• Macroeconomic and political uncertainties could impact the company's business and financial results.
• The company's ability to realize the anticipated benefits of its term loan facility is subject to certain conditions and milestones.

Future Outlook

Invivyd is targeting near-term profitability (1H 2025) with existing cash and cash equivalents, anticipated growth of net product revenue, and continued reduction of operating expenses. The company anticipates VYD2311 Phase 1 clinical trial data read-out later in Q2 2025 and discovery program updates on RSV and measles later in 2025.

Management Comments

• To drive long-term topline growth, we made a strategic decision to internalize our sales force at the beginning of 2025, said Bill Duke, Chief Financial Officer of Invivyd.
• Although this shift created a short-term headwind, we’re now seeing positive momentum with a return to growth and early signs of acceleration in Q2 2025.
• Backed by a strong cash position and potential to access up to $30 million in non-dilutive funding through our term loan facility, we remain focused on disciplined financial execution and continue to target profitability by the end of the first half of 2025.

Industry Context

Invivyd is operating in the competitive market of developing and commercializing treatments and preventatives for viral infectious diseases, particularly COVID-19. The company's focus on monoclonal antibodies and its efforts to expand its pipeline beyond SARS-CoV-2 into areas like RSV and measles reflect a broader industry trend of addressing unmet needs in infectious disease management.

Comparison to Industry Standards

• Invivyd's PEMGARDA is positioned as a pre-exposure prophylaxis for COVID-19 in immunocompromised individuals, similar to how AstraZeneca's Evusheld was initially used before losing its EUA due to variant resistance.
• The company's focus on a conserved epitope for its antibodies is a strategy to mitigate the risk of viral escape, a challenge faced by many COVID-19 therapeutics.
• Invivyd's move to internalize its sales force is a common strategy for pharmaceutical companies seeking to maximize control over commercialization efforts, although it can create short-term disruptions.
• The company's pursuit of a non-dilutive term loan facility is a typical financing strategy for biotech companies looking to extend their cash runway without diluting existing shareholders.
• Invivyd's exploration of RSV and measles targets aligns with the industry's ongoing efforts to develop novel vaccines and therapeutics for these common infectious diseases; for example, Merck is expected to launch Clesrovimab in 2025.

Related Party Transactions

• The document mentions related-party amounts included in accrued expenses and cost of product revenue for the three months ended March 31, 2025.

Stakeholder Impact

• Shareholders: The financial results and future outlook will impact shareholder value.
• Employees: The company's performance and strategic decisions will affect employee job security and opportunities.
• Customers (Healthcare Providers and Patients): The availability and efficacy of PEMGARDA and other products will impact patient care.
• Suppliers: The company's manufacturing and supply chain activities will affect its relationships with suppliers.
• Creditors: The company's financial performance will impact its ability to meet its debt obligations.

Next Steps

• Invivyd will continue to commercialize PEMGARDA and expand its sales and marketing efforts.
• The company will advance the development of VYD2311 and other pipeline candidates.
• Invivyd will engage with the FDA regarding potential regulatory pathways for its product candidates.
• The company will continue to monitor SARS-CoV-2 variants and assess the neutralizing activity of its antibodies.
• Invivyd will provide updates on its discovery programs for RSV and measles later in 2025.

Key Dates

Keywords

PEMGARDA, Invivyd, COVID-19, monoclonal antibody, EUA, VYD2311, profitability, financial results, SARS-CoV-2, immunocompromised, R&D, net revenue, clinical trial, RSV, measles